Data Presented To FDA Panel Show TAXUS Drug-Eluting Stents As Safe As Bare-Metal Stents And Far More Effective In Reducing Repeat Procedures

... Boston Scientific Corporation (NYSE: BSX) today presented data on its long- term randomized clinical trials to a special U.S. Food and Drug Administration (FDA) panel, showing that the TAXUS(R) paclitaxel-eluting coronary stent is as safe as bare-metal stents and far more effective in keeping arteries open and reducing the need for repeat procedures. [click link for full article] ...